Navigating Expanding Treatment Options for Plaque Psoriasis: A Conversation With Advanced Practice Providers

Lauren Miller, MPAS, PA-C; and Jayme Heim, MSN, FNP-BC, discuss the role of advanced practice providers (APPs) within dermatology, highlighting the medical, surgical, and cosmetic categories in the space.

An expert nurse practitioner comments on recent advances in the treatment of plaque psoriasis, as well as the continuous need for more treatment options.

Jayme Heim, MSN, FNP-BC; and Lauren Miller, MPAS, PA-C, share thoughts on the use of oral systemic and biologic treatments in plaque psoriasis, commenting on the need for personalized care for patients.

Experts in dermatology review the efficacy and safety of deucravacitinib in the treatment of plaque psoriasis, a recently approved oral TYK2 inhibitor.

Jayme Heim, MSN, FNP-BC, compares the efficacy, safety and dosing of 2 oral therapies, apremilast and deucravacitinib, for the treatment of plaque psoriasis.

Lauren Miller, MPAS, PA-C; and Jayme Heim, MSN, FNP-BC, share approaches to implementing the newly approved TYK2 inhibitor, deucravacitinib, into the treatment algorithm of plaque psoriasis.

An expert shares considerations for choosing between an oral therapy and a biologic injection when treating plaque psoriasis.

Experts in dermatology comment on tapinarof and roflumilast, 2 nonsteroidal topical therapies recently approved for treatment of plaque psoriasis.

Experts discuss access to treatment as one of the biggest barriers in plaque psoriasis and highlight the importance of individualizing therapy for each patient.

Experts share practice pearls for managing patients with plaque psoriasis, highlighting the need to educate health care providers about any dermatologic therapy before they commit to treating a patient.